{"organizations": [], "uuid": "a1a89e43864cc92253e03745a01b447317c14931", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aclaris-therapeutics-a-101-45-topi/brief-aclaris-therapeutics-a-101-45-topical-solution-meets-primary-all-secondary-endpoints-in-two-phase-2-clinical-trials-for-common-warts-idUSASB0C012", "country": "US", "domain_rank": 408, "title": "BRIEF-Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.355, "site_type": "news", "published": "2018-01-08T20:06:00.000+02:00", "replies_count": 0, "uuid": "a1a89e43864cc92253e03745a01b447317c14931"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aclaris-therapeutics-a-101-45-topi/brief-aclaris-therapeutics-a-101-45-topical-solution-meets-primary-all-secondary-endpoints-in-two-phase-2-clinical-trials-for-common-warts-idUSASB0C012", "ord_in_thread": 0, "title": "BRIEF-Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "aclaris therapeutics inc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Aclaris Therapeutics Inc:\n* ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS\n* ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS\n* ACLARIS THERAPEUTICS - ‍POSITIVE RESULTS FROM 2 PHASE 2 CLINICAL TRIALS,WART-202,WART-203 OF A-101 45% TOPICAL SOLUTION,FOR TREATMENT OF COMMON WARTS​\n* ACLARIS - ‍A-101 45% MET ALL PRIMARY,SECONDARY ENDPOINTS OF EACH TRIAL, ACHIEVING CLINICALLY,STATISTICALLY SIGNIFICANT CLEARANCE OF COMMON WARTS​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T20:06:00.000+02:00", "crawled": "2018-01-09T17:17:58.000+02:00", "highlightTitle": ""}